Thomas M Laursen1,2. 1. National Centre for Register-based Research, Aarhus BSS, Aarhus University. 2. The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark.
Abstract
PURPOSE OF REVIEW: The current review examines the recent literature on the causes of premature mortality in schizophrenia. RECENT FINDINGS: People with schizophrenia have higher premature mortality rates compared with the general population. Suicides and accidents account for a nontrivial part of the excess mortality, but the largest part is attributable to natural causes of death. Five major causes have been identified: first, adverse effects of medication; second, suboptimal lifestyle; third, somatic comorbidity; fourth, suboptimal treatment of somatic disorders; and fifth, accelerated ageing/genetic explanations. The positive aspect is that people with schizophrenia have increasing life expectancy, at least in high-income countries, and this development seems to largely follow the increase in the general population. Especially mortality rates from unnatural causes appear to have a positive impact. Nevertheless, despite more than 100 years of research and progress, the excess mortality in persons with schizophrenia remains unacceptably high, with no prospects of reaching the level in the general population. SUMMARY: The excess mortality in schizophrenia has received much focus. Future studies should explore the reasons for the high rates of natural causes of death, while aiming to disentangle the complex interplay between medication, lifestyle, comorbidity, treatment of somatic disorders, and genetic effects.
PURPOSE OF REVIEW: The current review examines the recent literature on the causes of premature mortality in schizophrenia. RECENT FINDINGS:People with schizophrenia have higher premature mortality rates compared with the general population. Suicides and accidents account for a nontrivial part of the excess mortality, but the largest part is attributable to natural causes of death. Five major causes have been identified: first, adverse effects of medication; second, suboptimal lifestyle; third, somatic comorbidity; fourth, suboptimal treatment of somatic disorders; and fifth, accelerated ageing/genetic explanations. The positive aspect is that people with schizophrenia have increasing life expectancy, at least in high-income countries, and this development seems to largely follow the increase in the general population. Especially mortality rates from unnatural causes appear to have a positive impact. Nevertheless, despite more than 100 years of research and progress, the excess mortality in persons with schizophrenia remains unacceptably high, with no prospects of reaching the level in the general population. SUMMARY: The excess mortality in schizophrenia has received much focus. Future studies should explore the reasons for the high rates of natural causes of death, while aiming to disentangle the complex interplay between medication, lifestyle, comorbidity, treatment of somatic disorders, and genetic effects.
Authors: Eleonora Gatta; Vikram Saudagar; Jenny Drnevich; Marc P Forrest; James Auta; Lindsay V Clark; Henry Sershen; Robert C Smith; Dennis R Grayson; John M Davis; Alessandro Guidotti Journal: Schizophr Bull Open Date: 2021-02-06
Authors: Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux Journal: Front Psychiatry Date: 2022-01-13 Impact factor: 4.157
Authors: Arianna De Rosa; Andrea Fontana; Tommaso Nuzzo; Martina Garofalo; Anna Di Maio; Daniela Punzo; Massimiliano Copetti; Alessandro Bertolino; Francesco Errico; Antonio Rampino; Andrea de Bartolomeis; Alessandro Usiello Journal: Schizophrenia (Heidelb) Date: 2022-02-25
Authors: Anna Di Maio; Arianna De Rosa; Silvia Pelucchi; Martina Garofalo; Benedetta Marciano; Tommaso Nuzzo; Fabrizio Gardoni; Andrea M Isidori; Monica Di Luca; Francesco Errico; Andrea De Bartolomeis; Elena Marcello; Alessandro Usiello Journal: Int J Mol Sci Date: 2022-01-28 Impact factor: 5.923
Authors: Johanna Breilmann; Steffi G Riedel-Heller; Uta Gühne; Alexander Pabst; Markus Kösters; Alkomiet Hasan; Peter Falkai; Reinhold Kilian; Andreas Allgöwer; Klemens Ajayi; Jessica Baumgärtner; Peter Brieger; Karel Frasch; Stephan Heres; Markus Jäger; Andreas Küthmann; Albert Putzhammer; Bertram Schneeweiß; Michael Schwarz; Thomas Becker Journal: J Occup Med Toxicol Date: 2022-01-18 Impact factor: 2.646